Physician profile
Qili Li
NPI 1871564971
$2,542.57
in general payments reported to CMS, 2019-2025
12 companies · $130 in 2025
The $130 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $507 · 2020: $322 · 2021: $389 · 2022: $783 · 2023: $202 · 2024: $209 · 2025: $130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $501 · Education: $40.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $500.94 |
| Education | $40.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $882.37 | 2019-2024 | Evenity, Prolia |
| Merz North America, INC. | $655.78 | 2022-2024 | |
| Pfizer INC. | $451.97 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $130.05 | 2025 | Ultomiris |
| Intercept Pharmaceuticals, INC. | $125.00 | 2022 | |
| Therapeuticsmd, INC. | $71.63 | 2019 | |
| Gilead Sciences, INC. | $69.00 | 2019 | |
| Myovant Sciences INC. | $47.69 | 2021-2022 | |
| Millicent US INC | $40.05 | 2024 | |
| Abbvie INC. | $31.56 | 2020-2021 | |
| Allergan, INC. | $20.61 | 2019 | |
| Vertical Pharmaceuticals, LLC | $16.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Qili Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.